Myxedema Coma Induced by Short-term Amiodarone Therapy

Agarwal, Vratika; Parikh, Valay; Otterbeck, Philip; Lafferty, James

doi:10.1097/maj.0000000000000241

Cited by 6 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We therefore assumed that drug-induced hypothyroidism may induce a rapidly progressive disturbance in thyroid hormone production in comparison to patients with primary idiopathic hypothyroidism, thus leading to the development of decompensated hypothyroidism within a short period of time. In fact, the occurrence of a myxedema coma, which developed after only five months of amiodarone therapy, similar to our case, has been previously reported ( 9 ).…”

Section: Discussionsupporting

confidence: 91%

Myxedema Coma Following the Administration of Gonadotropin-releasing Hormone Agonist Complicated by Acute Pancreatitis

et al. 2018

View full text Add to dashboard Cite

Gonadotropin-releasing hormone (GnRH) agonists have been used for the treatment of various diseases. Although autoimmune thyroid disease has been reported as a rare complication of these agents, the symptoms are almost always transient and non-life-threatening. We herein report a rare case of an 83-year-old man receiving GnRH agonist treatment for prostate cancer who developed myxedema coma complicated by acute pancreatitis. This is the first report of myxedema coma potentially associated with a GnRH agonist. The follow-up of the thyroid function is necessary for patients undergoing treatment with GnRH agonists, especially those known to have or to be susceptible to autoimmune thyroid disease.

show abstract

Section: Discussionsupporting

confidence: 91%

Myxedema Coma Following the Administration of Gonadotropin-releasing Hormone Agonist Complicated by Acute Pancreatitis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5] In this article, we describe a rare case of a MC in an elderly female under amiodarone therapy with no previous history of thyroid disease, which was successfully treated. Note.…”

Section: Discussionmentioning

confidence: 99%

“…[1] However, myxoedema coma (MC) secondary to amiodarone therapy has been sparsely reported. [1][2][3][4][5] Although it is usually seen in patients with underlying thyroid disease, it can be the first manifestation of hypothyroidism. Due to its systemic involvement, the mortality rate is high (up to 50%).…”

Section: Introductionmentioning

confidence: 99%

Amiodarone-induced myxoedema coma as a rare differential diagnosis of consciousness disturbance

Martins

Rosa

Oliveira

2017

CRIM

View full text Add to dashboard Cite

Myxoedema coma is an uncommon and life-threatening endocrine emergency with a high mortality rate. This entity is the extreme expression of severe hypothyroidism and the cardinal features are decreased mental status and hypothermia. Diagnosis is challenging and a high index of suspicion is crucial because it allows an early recognition of this condition and prompt initiation of supportive measures along with adequate thyroid replacement therapy. Herein, we report an extremely rare case of myxoedema coma secondary to amiodarone in a 90-year-old female with no previous history of thyroid disease, which was successfully treated with thyroid hormone replacement. Although its rarity, we emphasize that myxoedema coma should be included in the differential diagnosis of consciousness disturbances, particularly in patients under amiodarone therapy.

show abstract

“…Leading precipitating factors include stress, infection, and septicemia [9,10]. It has been reported recently that the mortality rate of individuals suffering from MC is 40% [11][12][13]. A report from Spain presents a global incidence rate of 220,000 per year, also commonly found in women and elderly [14][15].…”

Section: Introductionmentioning

confidence: 99%

Amiodarone-Induced Myxedema Coma

Raeouf¹,

Goyal²,

Traylor³

2020

Cureus

View full text Add to dashboard Cite

Amiodarone is a class III antiarrhythmic drug often used to treat supraventricular and ventricular arrhythmias with high efficacy. Amiodarone is associated with thyroid dysfunction, which can lead to myxedema coma (MC) in undiagnosed cases. Amiodarone-induced MC is a life-threatening condition that presents a complex diagnostic challenge to emergency physicians. A 71-year-old male with a past medical history of congestive heart failure presented unresponsive to the emergency department with bradycardia and syncope. His medications included amiodarone. Work-up showed hypothermia, thyroid-stimulating hormone (TSH) of 52.2 uIU/mL, and low free T 4 of 0.64 ng/dL. This case suggests the importance of thyroid panels in the management of patients who are using amiodarone longterm. This case also highlights a simple and effective treatment for amiodarone-induced MC.

show abstract

Myxedema Coma Induced by Short-term Amiodarone Therapy

Cited by 6 publications

References 8 publications

Myxedema Coma Following the Administration of Gonadotropin-releasing Hormone Agonist Complicated by Acute Pancreatitis

Myxedema Coma Following the Administration of Gonadotropin-releasing Hormone Agonist Complicated by Acute Pancreatitis

Amiodarone-induced myxoedema coma as a rare differential diagnosis of consciousness disturbance

Amiodarone-Induced Myxedema Coma

Contact Info

Product

Resources

About